{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:46Z","timestamp":1793042686774,"version":"4.5.0"},"reference-count":13,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"MaryJo & Brian C. Rogers Fund","award":["Not applicable."],"award-info":[{"award-number":["Not applicable."]}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["Not applicable."],"award-info":[{"award-number":["Not applicable."]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013041","name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy","doi-asserted-by":"crossref","award":["Not Applicable."],"award-info":[{"award-number":["Not Applicable."]}],"id":[{"id":"10.13039\/100013041","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["Not applicable."],"award-info":[{"award-number":["Not applicable."]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019050","name":"Barney Family Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019050","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Laverna Hahn Charitable Trust (SLT)."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Neoadjuvant (presurgical) anti-programmed cell death protein-1 (PD-1)-based immunotherapy as a new approach to cancer treatment has been developing on an accelerated trajectory since the seminal clinical trial results from studies in lung cancer and melanoma were published in 2018. Groundbreaking regulatory approvals in triple-negative breast cancer, non-small cell lung cancer and melanoma will certainly be followed by additional approvals in other disease indications, as clinical and basic research are burgeoning globally in hundreds of clinical trials across dozens of cancer types. As this field is evolving, it is addressing gaps in our understanding of biological mechanisms underlying PD-1 pathway blockade and their synergy with other antineoplastic drugs, probing mechanisms of response and resistance to neoadjuvant immunotherapy, optimizing efficacious clinical strategies, and analyzing commonalities and differences across cancer types. Knowledge gained thus far provides a firm foundation from which to launch the next phase of translational research in this expanding arena of biomedical investigation.<\/jats:p>","DOI":"10.1136\/jitc-2024-010833","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:23Z","timestamp":1737676823000},"page":"e010833","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0821-8587","authenticated-orcid":false,"given":"Suzanne L","family":"Topalian","sequence":"first","affiliation":[{"name":"Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"The Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA"},{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew M","family":"Pardoll","sequence":"additional","affiliation":[{"name":"The Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA"},{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA"},{"name":"Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2025100311163756000_13.1.e010833.1","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"2025100311163756000_13.1.e010833.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"2025100311163756000_13.1.e010833.3","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.xcrm.2024.101412","article-title":"Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma","volume":"5","author":"Pulliam","year":"2024","journal-title":"Cell Rep Med"},{"key":"2025100311163756000_13.1.e010833.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2025100311163756000_13.1.e010833.5","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100311163756000_13.1.e010833.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651"},{"key":"2025100311163756000_13.1.e010833.7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"2025100311163756000_13.1.e010833.8","first-page":"4","article-title":"ODAC vote will likely lead to three-arm and four-arm designs \u2013 and pragmatic trials \u2013 for perioperative indications","volume":"50","author":"Cobb","year":"2024","journal-title":"The Cancer Let"},{"key":"2025100311163756000_13.1.e010833.9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100311163756000_13.1.e010833.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"PL02.08 Perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2025100311163756000_13.1.e010833.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011"},{"key":"2025100311163756000_13.1.e010833.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03752-4"},{"key":"2025100311163756000_13.1.e010833.13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:16:44Z","timestamp":1759515404000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-010833"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010833","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}